Drug Profile
Clobetasol propionate oral - AFYX Therapeutics
Alternative Names: Rivelin® Clobetasol patch; Rivelin®-CLOLatest Information Update: 03 May 2023
Price :
$50
*
At a glance
- Originator Dermtreat
- Developer AFYX Therapeutics
- Class Anti-inflammatories; Antipsoriatics; Antiulcers; Fluorinated steroids; Glucocorticoids; Halogenated hydrocarbons; Propionates
- Mechanism of Action Steroid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Lichen planus
- Preclinical Aphthous stomatitis
Most Recent Events
- 03 May 2023 Preclinical trials in Aphthous stomatitis in Denmark (Topical) (AFYX Therapeutics pipeline, May 2023)
- 26 Jul 2022 Clobetasol proprionate oral is still in phase II trials for Lichen planus in Germany and Canada (AFYX Therapeutics pipeline, July 2022)
- 15 Apr 2021 Efficacy and safety data from a phase II trial in Lichen planus presented at the American Academy of Oral Medicine Virtual Annual Conference (AAOM-2021)